NEW YORK (TheStreet) -- RATINGS CHANGES

ComScore ( SCOR) was downgraded to neutral from buy by Goldman Sachs, which cited valuation, based on a 12-month price target of $57.

Crown Holdings (CCK) was downgraded to buy from neutral by Goldman, citing valuation based on a 12-month price target of $59.

EMC (EMC) was downgraded to market perform from outperform by FBR Capital Markets, which set a 12-month price target of $28, saying that EMC's fundamentals are weakening.

Idera Phamaceuticals (IDRA) was started at overweight by J.P. Morgan, which set a 12-month price target of $6. The company's lead asset, IMO-8400, is being studied in two phase 1/2 proof-of-concept studies in MYD88 positive Waldenstrom's macroglobulinemia (WM) and diffuse large B-cell lymphoma (DLBCL), J.P. Morgan said.

Jabil Circuit (JBL) was upgraded to buy from hold by Needham, which said Jabil is performing well with Apple (AAPL) and other mobile customers.

Ligand Pharmaceuticals (LGND) was downgraded to hold from buy by Deutsche Bank, which cited valuation based on a 12-month price target of $94.

Lowe's (LOW) was upgraded to outperform from neutral by Wedbush, which set a 12-month price target of $82, saying that Lowe's is taking market share from Sears (SHLD) and is leveraged to lower interest rates.

Mattress Firm (MFRM) was downgraded to neutral from outperform by Wedbush, which set a 12-month price target of $60, saying the company is facing multiple growth headwinds.

If you liked this article you might like

Diversity in Film Is Translating Into Big Box-Office Receipts

Starboard's Smith Seeks to Compel ComScore to Hold Annual Meeting

Superhero Shows Are Coming to Amazon, Netflix and Hulu -- Can They Boost Subscribers?

Disney Is Remaking Almost All of its Entire Animated Catalog -- Here Are 11 Upcoming Movies

New 'Spider-Man' Will Swing to the No. 1 Spot at the Box Office This Weekend